potent, oral heme-displacing IDO1 inhibitor

low predicted human dose (<10 mg QD)

from ALIS mass-based binding screen + SBDD

ACS Med. Chem. Lett., Jul. 15, 2020

Merck & Co., Boston, MA

“compound 2” is a heme-displacing IDO1 inhibitor with a similar binding mode to BMS-986205 with a low projected human dose. A bis-amide hit was generated from a mass-spectrometry based binding…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks